🇺🇸 FDA
Patent

US 11718621

Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

granted A61KA61K45/06A61P

Quick answer

US patent 11718621 (Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use) held by SPERO THERAPEUTICS, INC. expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SPERO THERAPEUTICS, INC.
Grant date
Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K45/06, A61P, A61P31/04